Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 2,075,339 |
|
|||||
| News | - | ||||||
| Day High | 4.36 | Low High |
|||||
| Day Low | 4.08 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Novavax Inc | NVAX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.17 | 4.18% | 4.24 | 13:42:17 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.09 | 4.08 | 4.36 | 4.07 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 10,443 | 2,075,339 | $ 4.26 | $ 8,833,922 | - | 3.5324 - 11.36 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:42:29 | 95 | $ 4.24 | USD |
Novavax Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 590.6M | 139.95M | - | 983.71M | -545.06M | -3.89 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Novavax News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVAX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.07 | 4.36 | 3.81 | 3.96 | 3,037,254 | 0.17 | 4.18% |
| 1 Month | 4.89 | 4.95 | 3.81 | 4.36 | 3,719,979 | -0.65 | -13.29% |
| 3 Months | 4.18 | 6.05 | 3.5324 | 4.74 | 7,414,177 | 0.06 | 1.44% |
| 6 Months | 6.35 | 7.49 | 3.5324 | 5.08 | 7,330,269 | -2.11 | -33.23% |
| 1 Year | 8.527 | 11.36 | 3.5324 | 6.54 | 7,620,317 | -4.29 | -50.28% |
| 3 Years | 207.50 | 277.7999 | 3.5324 | 54.82 | 6,343,501 | -203.26 | -97.96% |
| 5 Years | 10.40 | 331.5388 | 3.5324 | 61.59 | 5,697,586 | -6.16 | -59.23% |
Novavax Description
| Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. |
